NVCRHIGH SIGNALFINANCIAL10-K

NVCR underwent a major balance sheet restructuring with current liabilities dropping 70.5% and total assets declining 35.2%, while operating cash flow deteriorated significantly and interest expense nearly doubled.

The dramatic reduction in liabilities suggests a major debt restructuring or conversion event, which aligns with the removal of convertible note dilution language from risk factors. However, the company's operational performance is weakening with operating cash flow declining 85.9% and cash reserves dropping 42.9%, indicating potential liquidity pressures despite the balance sheet restructuring.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

NVCR shows signs of a major financial restructuring with current liabilities falling 70.5% from $756.4M to $223.2M and total assets declining 35.2% to $804.3M, suggesting significant debt conversion or settlement activity. Despite reducing net losses by 19.2%, operational cash flow deteriorated sharply by 85.9% to -$49.0M while cash reserves dropped 42.9% to $93.5M, indicating underlying business challenges persist. The 90.5% increase in interest expense to $22.2M, combined with declining cash and worsening operating cash flow, signals potential liquidity concerns despite the apparent debt restructuring.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+90.5%
$11.7M$22.2M

Interest expense surged 90.5% — significant debt increase or rising rates materially impacting earnings.

Operating Cash Flow
Cash Flow
-85.9%
-$26.4M-$49.0M

Operating cash flow fell 85.9% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Liabilities
Balance Sheet
-70.5%
$756.4M$223.2M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-47.3%
$880.6M$463.9M

Liabilities reduced 47.3% — deleveraging improves balance sheet strength and financial flexibility.

Cash & Equivalents
Balance Sheet
-42.9%
$163.8M$93.5M

Cash declined 42.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-41.6%
$1.1B$646.7M

Current assets declined 41.6% — monitor working capital adequacy and short-term liquidity.

Capital Expenditure
Cash Flow
-37.8%
$42.9M$26.6M

Capex reduced 37.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Assets
Balance Sheet
-35.2%
$1.2B$804.3M

Total assets contracted 35.2% — asset sales, write-downs, or balance sheet optimization underway.

Accounts Receivable
Balance Sheet
+20.5%
$74.2M$89.4M

Receivables grew 20.5% — monitor days sales outstanding for collection efficiency.

Net Income
P&L
+19.2%
-$168.6M-$136.2M

Net income grew 19.2% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
lawmakers to agree on a budget or appropriation legislation to fund the federal government s operations (also known as a government shutdown), which could have an adverse effect on regulatory agencies, such as the U.S.
PMA processing) and Centers for Medicare Medicaid Services (e.g.
payment processing), to perform their duties the impact our operations and the financial markets and other businesses reactions to any such failure, or other disruptions outside of our control; our cash needs; and our prospects, financial condition and results of operations.
BUSINESS Overview We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells.
Our key priorities are to drive commercial adoption of Optune Gio , Optune Lua , and Optune Pax , our commercial TTFields therapy devices, obtain regulatory approval to market TTFields therapy devices in new indications, such as brain metastases from non-small cell lung cancer ("NSCLC"), and to advance clinical and product development programs intended to extend overall survival in some of the most aggressive forms of cancer.
+7 more — sign up free →
REMOVED
Transactions relating to our convertible notes may dilute the ownership interest of existing shareholders, or may otherwise depress the price of our ordinary shares.
BUSINESS Overview We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.
Our key priorities are to drive commercial adoption of Optune Gio and Optune Lua , our commercial TTFields therapy devices, and to advance clinical and product development programs intended to extend overall survival in some of the most aggressive forms of cancer.
Our therapy is delivered through a medical device and we continue to advance our Products with the intention to extend survival and maintain quality of life for patients.
Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer ("NSCLC") concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →